2020 ASCO Virtual Direct™ Highlights


 

2020 ASCO Update on ctDNA: Can We Use ctDNA as a Marker of MRD Following Definitive Treatment in Localized NSCLC? Is the Absence of Detectable BRAFV600 ctDNA at Baseline Associated With Improved PFS and OS in Pts Receiving Dabrafenib and Trametinib?

125 views
November 11, 2020
Comments 0
Login to view comments. Click here to Login